The company is on track to file an IND for PRT13722 in mid-2026 and to start a Phase 1 clinical trial in H2 2026. In April 2026, Prelude raised $90.0 million in gross proceeds through an underwritten offering, positioning the company for clinical advancement of its lead programs. The company leverages expertise in targeted protein degradation to develop differentiated oncology therapies.
Cyborg Score Rationale
Prelude has initiated Phase 1 enrollment for its JAK2V617F program and is advancing PRT13722 toward IND filing. Recent capital raise provides runway, and preclinical data shows promise. However, as a clinical-stage company with no approved products, execution risk is elevated and the path to profitability remains uncertain.
Top Insights
PRT13722 demonstrates complete tumor regressions as monotherapy in breast cancer models with improved hematological safety
Incyte has an exclusive option to acquire the JAK2V617F program for potential $100 million milestone, de-risking development
$90 million capital raise in April 2026 funds continued R&D and clinical development
New Chief Medical Officer appointed in April 2026 with 30+ years of oncology drug development experience
Named Competitors
Imbruvica — JAK inhibitor for hematologic malignancies
VERZENIO — CDK4/6 inhibitor for ER+ breast cancer
Ibrance — CDK4/6 inhibitor for hormone receptor-positive breast cancer